Home > Neurology > ECTRIMS 2021 > Experimental Treatments > Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial

Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial

Presented By
Prof. Peter Calabresi, Johns Hopkins University, MD, USA
Conference
ECTRIMS 2021
Trial
Phase 2, AFFINITY
Opicinumab did not meet the primary or key secondary efficacy endpoints in patients with relapsing MS. Subgroup analyses demonstrated potential benefits of opicinumab for older patients, patients with longer disease duration, patients with higher Expanded Disability Status Scale (EDSS) scores, and patients who received dimethyl fumarate as a disease-modifying therapy (DMT) [1]. Opicinumab is a human monoclonal antibody, blocking LINGO-1, a leucine-rich repeat protein. The SYNERGY trial (NCT01864148) –a previous opicinumab study– did not demonstrate a significant improvement of disability following opicinumab treatment, compared with placebo in patients with relapsing MS [2]. However, further analysis showed that a subgroup of patients, defined by disease duration, magnetisation transfer ratios, and diffusion tensor imaging-radial diffusion in pre-existing T2 lesion...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on